多巴胺受体拮抗剂与部分激动剂对健康志愿者谷氨酸能系统的影响:双盲随机安慰剂对照1H-MRS交叉研究
该研究采用双盲、自身对照、交叉、安慰剂对照设计,在健康志愿者中比较阿立哌唑(多巴胺D2受体部分激动剂)与氨磺必利(多巴胺D2受体拮抗剂)对前扣带回皮层、纹状体和丘脑谷氨酸能代谢物的影响。结果显示,阿立哌唑较安慰剂显著升高Glx水平(β=0.55,95%CI [0.15, 0.95],P=0.007),氨磺必利有升高趋势但未达统计学显著性。
要点
- 阿立哌唑7天给药较安慰剂显著升高健康志愿者脑内Glx水平。
- 氨磺必利虽观察到Glx升高趋势,但未达统计学显著性。
- 调整血浆母药及活性代谢物浓度后,阿立哌唑效应仍显著。
核心结论
- 健康参与者接受阿立哌唑1周后,脑Glx水平较安慰剂给药发生改变。
- 该发现为抗精神病药治疗与脑代谢物关系提供了新见解。
研究设计与样本
- 采用双盲、自身对照、交叉、安慰剂对照研究设计,分两臂(每臂n=25)。
- 健康志愿者接受阿立哌唑(至10 mg/天)或氨磺必利(至400 mg/天)各7天,并以伪随机顺序接受相应安慰剂期。
- 使用1H-MRS在基线、用药1周后和安慰剂1周后三个时间点测量谷氨酸能代谢物水平。
- 数值分析为前扣带回皮层、纹状体和丘脑的合并测量。
主要发现
- 阿立哌唑较安慰剂显著升高谷氨酸+谷氨酰胺(Glx)水平(β=0.55,95%CI [0.15, 0.95],P=0.007)。
- 基线时平均Glx水平为8.14 institutional units(s.d.=2.15)。
- 阿立哌唑治疗后平均Glx水平为8.16 institutional units(s.d.=2.40),安慰剂为7.61 institutional units(s.d.=2.36)。
- 调整血浆母药及活性代谢物药物水平后,阿立哌唑效应仍显著。
- 氨磺必利观察到Glx升高但未达统计学显著性。
临床怎么用
- 提示多巴胺D2受体部分激动剂阿立哌唑可调节健康大脑谷氨酸能代谢物水平。
- 为理解抗精神病药对谷氨酸能系统的作用机制提供了健康志愿者证据。
局限性
- 研究在健康志愿者中进行,结果不能直接外推至精神病性障碍患者。
- 样本为每臂25例健康志愿者,样本量有限。
- 氨磺必利对Glx的效应未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeting the glutamatergic system is posited as a potentially novel therapeutic strategy for psychotic disorders. While studies in subjects indicate that antipsychotic medication reduces brain glutamatergic measures, they were unable to disambiguate clinical changes from drug effects. AIMS: To address this, we investigated the effects of a dopamine D2 receptor partial agonist (aripiprazole) and a dopamine D2 receptor antagonist (amisulpride) on glutamatergic metabolites in the anterior cingulate cortex (ACC), striatum and thalamus in healthy controls. METHOD: A double-blind, within-subject, cross-over, placebo-controlled study design with two arms (n = 25 per arm) was conducted. Healthy volunteers received either aripiprazole (up to 10 mg/day) for 7 days or amisulpride (up to 400 mg/day) and a corresponding period of placebo treatment in a pseudo-randomised order. Magnetic resonance spectroscopy (1H-MRS) was used to measure glutamatergic metabolite levels and was carried out at three different time points: baseline, after 1 week of drug and after 1 week of placebo. Values were analysed as a combined measure across the ACC, striatum and thalamus. RESULTS: Aripiprazole significantly increased glutamate + glutamine (Glx) levels compared with placebo (β = 0.55, 95% CI [0.15, 0.95], P = 0.007). At baseline, the mean Glx level was 8.14 institutional units (s.d. = 2.15); following aripiprazole treatment, the mean Glx level was 8.16 institutional units (s.d. = 2.40) compared with 7.61 institutional units (s.d. = 2.36) for placebo. This effect remained significant after adjusting for plasma parent and active metabolite drug levels. There was an observed increase with amisulpride that did not reach statistical significance. CONCLUSIONS: One week of aripiprazole administration in healthy participants altered brain Glx levels as compared with placebo administration. These findings provide novel insights into the relationship between antipsychotic treatment and brain metabolites in a healthy participant cohort.
引用
- Zahid U, Osugo M, Selvaggi P, et al. The effects of dopamine receptor antagonist and partial agonist antipsychotics on the glutamatergic system: double-blind, randomised, placebo-controlled 1H-MRS cross-over study in healthy volunteers. Br J Psychiatry. 2025. PMID: 40698574. doi:10.1192/bjp.2025.10319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。